Andrew Gu was appointed Director of Cellectar Biosciences, Inc. As of November 6, 2026, Cellectar Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 18, 2026, naming 2 appointments (Form 8-K, May 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cellectar Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cellectar Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-18. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Cellectar Biosciences, Inc. files it.
Also on the record for Cellectar Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by BALYASNY ASSET MANAGEMENT L.P. | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Caligan Partners LP | 5.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by SilverArc Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by StemPoint Capital LP | 9.9% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Bleichroeder LP | 9.99% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G, by Empery Asset Management, LP | 9.99% of the class | 5%+ stakes | Source |
| June 5, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 9.99% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13G, by Stonepine Capital Management, LLC | 9.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Bleichroeder LP | 4.61% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Rosalind Advisors, Inc. | 5.5% of the class | 5%+ stakes | Source |
| February 4, 2026 | Stake report, Schedule 13G/A, by Hexstone Capital LLC | 4.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Bleichroeder LP | 6.08% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cellectar Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cellectar Biosciences, Inc. and the records around it.
Cellectar Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- StemPoint Capital LP also filed stake reports on 4 other companies: Faeth Therapeutics, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026), Xilio Therapeutics, Inc. (Aug 2026)
- Hexstone Capital LLC also filed stake reports on 6 other companies: Jet.AI Inc. (Nov 2026), Actuate Therapeutics, Inc. (Oct 2026), Global Mofy AI Ltd (May 2026)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026), Fractyl Health Inc (May 2026)
Watch Cellectar Biosciences, Inc.
Get an email when Cellectar Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cellectar Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Cellectar Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cellectar Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-18 | In | Director | 8-K, 2026-05-18 | ||
| 2026-05-18 | In | 8-K, 2026-05-18 |
Who leads Cellectar Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Andrew Gu, appointed (filed 2026-05-18).
New leaders reset buying decisions — get the Full Report on Cellectar Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Cellectar Biosciences, Inc., with the record behind each one.
Find candidates like Director at Cellectar Biosciences, Inc.Every change, in the filing's words
Appointed: Andrew Gu, Director
On May 18, 2026, the Board appointed Mr. Gu to serve as a member of the Board as a Class III director.
Appointed: Andrew Gu
The Board also appointed Mr. Gu to serve as a member of the Audit Committee of the Board.
- On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the "Board") of Cellectar Biosciences, Inc. (the "Company"), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the "Annual Meeting"), at which time his current term as a director will expire.
- Dr. Loren's decision to not to stand for reelection was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Company has entered into a consulting agreement with Dr. Loren, effective July 8, 2026.
- Dr. Loren will provide consulting services promoting the success of the Company for a term of one year and will be compensated $15,000 per quarter during the term.
- Additionally, at the end of the term, Dr. Loren will receive a stock option grant of 15,000 shares.
- The granted options and the option grants that he has previously received shall remain exercisable for 10 years from their respective grant dates.
- As previously announced, the Company entered into a securities purchase agreement on May 4, 2026, with certain institutional investors to issue and sell shares of the Company's common stock, and concurrently entered into a letter agreement (the "Board Designation Side Letter") with Nantahala Capital Management, LLC ("Nantahala").
Tools for this story
Each opens in a new tab, filled in for Cellectar Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.